CC Bio, developer of preventative solutions for microbiome dysbiosis, announced today it has been awarded further continuity funding of £29,800 from Innovate UK, the UK’s innovation agency, to support its ongoing Innovate UK smart grant.
The continuity funding will supplement the company’s existing research project, entitled “Development of clinically translatable therapies for the treatment and prevention of bacterial vaginosis”, and help minimise disruption caused by the Covid-19 global pandemic.
The funding helps maintain active collaboration between CC Bio and Brunel University.
“The Covid-19 pandemic has profoundly affected all aspects of our personal and professional lives" said Dr. Matthew Cummings, CEO and co-founder of CC Bio.
“Closures to university facilities, while necessary to prevent community spread of the virus and save lives, have had significant and unexpected impact on our project timelines and costs. We are grateful that Innovate UK have recognised the implications of governmental restrictions on our active project and awarded further funding to help us overcome them. The steps we have taken towards ground-breaking therapeutics for the treatment of Bacterial Vaginosis are exciting, and this further funding represents an endorsement of our progress and project management by Innovate UK. "
About InnovateUK
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk
About CC Bio.
CC Bio harnesses the power of bacteriophage to modify the composition of a number of human microbiome environments, resolving dysbiosis before manifestation of disease. Current active therapeutic programmes include bacterial vaginosis, and additional human health applications.
CC Bio was founded in 2018, emerging from Deep Science Ventures, an early stage venture creation programme which aims to address the largest STEM challenges worldwide and has been further fostered by the Accelerate@Babraham programme at the Babraham Research Campus, Cambridge. CC Bio continues to build out a world-class, patent-protected IP portfolio generated by its drug discovery programme. We are interested in partnerships to expedite the progress of their research programmes, and to explore new opportunities in microbiome manipulation. CC Bio are currently fundraising and seek to close their seed round in late September.